Symbols / AMLX
AMLX Chart
About
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 1.62B |
| Enterprise Value | 1.28B | Income | -149.28M | Sales | -665.00K |
| Book/sh | 3.02 | Cash/sh | 3.13 | Dividend Yield | — |
| Payout | 0.00% | Employees | 123 | IPO | — |
| P/E | — | Forward P/E | -11.19 | PEG | — |
| P/S | -2429.24 | P/B | 4.86 | P/C | — |
| EV/EBITDA | -6.62 | EV/Sales | -1920.89 | Quick Ratio | 13.35 |
| Current Ratio | 13.70 | Debt/Eq | 1.79 | LT Debt/Eq | — |
| EPS (ttm) | -1.79 | EPS next Y | -1.31 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-03 | ROA | -39.44% |
| ROE | -56.53% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 291.04% | Profit Margin | 0.00% | Shs Outstand | 109.82M |
| Shs Float | 82.23M | Short Float | 13.55% | Short Ratio | 7.15 |
| Short Interest | — | 52W High | 17.49 | 52W Low | 2.60 |
| Beta | -0.30 | Avg Volume | 1.46M | Volume | 1.31M |
| Target Price | $21.67 | Recom | Strong_buy | Prev Close | $13.90 |
| Price | $14.71 | Change | 5.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.67
Mean price target
2. Current target
$14.71
Latest analyst target
3. DCF / Fair value
$-19.36
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.71
Low
$19.00
High
$28.00
Mean
$21.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-20 | main | B of A Securities | Buy → Buy | $19 |
| 2026-02-10 | main | HC Wainwright & Co. | Buy → Buy | $28 |
| 2025-11-07 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-10-17 | main | Citigroup | Buy → Buy | $20 |
| 2025-10-16 | main | Baird | Outperform → Outperform | $19 |
| 2025-10-03 | main | B of A Securities | Buy → Buy | $16 |
| 2025-09-16 | main | Goldman Sachs | Buy → Buy | $20 |
| 2025-09-15 | main | Guggenheim | Buy → Buy | $25 |
| 2025-08-28 | main | B of A Securities | Buy → Buy | $14 |
| 2025-06-24 | init | Guggenheim | — → Buy | $17 |
| 2025-06-17 | init | Citigroup | — → Buy | $12 |
| 2025-05-14 | main | Mizuho | Outperform → Outperform | $8 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-05-07 | up | Leerink Partners | Market Perform → Outperform | $10 |
| 2025-04-07 | up | Mizuho | Neutral → Outperform | $7 |
| 2025-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-05 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-18 | up | Baird | Neutral → Outperform | $11 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-10-18 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
- Amylyx schedules March 3 call on 2025 results and company updates - Stock Titan ue, 24 Feb 2026 14
- AMLX: B of A Securities Raises Target Price, Maintains Buy Ratin - GuruFocus Sat, 21 Feb 2026 02
- HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire hu, 29 Jan 2026 08
- Precision Trading with AMLX Company (AMLX) Risk Zones - Stock Traders Daily Fri, 20 Feb 2026 15
- Is AMLX Stock a Solid Choice Right Now? - Nasdaq hu, 16 Oct 2025 07
- Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million - The Motley Fool Sat, 31 Jan 2026 08
- Amylyx Pharmaceuticals (AMLX): Assessing Valuation After a Dramatic 260% Share Price Surge - Yahoo Finance Sun, 26 Oct 2025 07
- Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data - Quiver Quantitative Sun, 04 Jan 2026 08
- Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - simplywall.st Sun, 05 Oct 2025 07
- Amylyx Pharmaceuticals: Back From The Dead (NASDAQ:AMLX) - Seeking Alpha ue, 27 Jan 2026 08
- What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now? - Yahoo Finance Fri, 24 Oct 2025 07
- Insider Sale: Co-Chief Executive Officer of $AMLX Sells 136,193 Shares | AMLX Stock News - Quiver Quantitative Wed, 21 Jan 2026 08
- With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? - The Motley Fool Wed, 03 Dec 2025 08
- Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation - simplywall.st Mon, 01 Sep 2025 07
- 5 Major Wall Street Conferences in 9 Days: Amylyx Pharmaceuticals' Packed September Schedule - Stock Titan ue, 26 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3557 | 52097 | — | Sale at price 14.65 per share. | FRATES JAMES MATTHEW | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 15500 | 227593 | — | Sale at price 14.68 per share. | COHEN JOSHUA BARRY | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 15500 | 227618 | — | Sale at price 14.68 per share. | KLEE JUSTIN B | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 3448 | 50516 | — | Sale at price 14.65 per share. | MAZZARIELLO GINA | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 138167 | 1878094 | — | Sale at price 13.59 - 13.83 per share. | COHEN JOSHUA BARRY | Chief Executive Officer | — | 2026-01-16 00:00:00 | D |
| 5 | 200000 | 1514000 | — | Conversion of Exercise of derivative security at price 7.57 per share. | COHEN JOSHUA BARRY | Chief Executive Officer | — | 2026-01-16 00:00:00 | D |
| 6 | 138188 | 1877570 | — | Sale at price 13.58 - 13.89 per share. | KLEE JUSTIN B | Chief Executive Officer | — | 2026-01-16 00:00:00 | D |
| 7 | 200000 | 1514000 | — | Conversion of Exercise of derivative security at price 7.57 per share. | KLEE JUSTIN B | Chief Executive Officer | — | 2026-01-16 00:00:00 | D |
| 8 | 17780 | — | — | Stock Gift at price 0.00 per share. | MILNE GEORGE MCLEAN JR | Director | — | 2026-01-12 00:00:00 | D |
| 9 | 3326 | 36954 | — | Sale at price 11.11 per share. | FRATES JAMES MATTHEW | Chief Financial Officer | — | 2026-01-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -59.05K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.09 | 0.21 | 0.00 |
| NormalizedEBITDA | -195.72M | 39.89M | -200.85M | -82.64M |
| TotalUnusualItems | -59.05M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | -59.05M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -301.74M | 49.27M | -198.38M | -87.93M |
| ReconciledDepreciation | 904.00K | 1.09M | 487.00K | 52.00K |
| ReconciledCostOfRevenue | 124.63M | 25.44M | 2.99M | 0.00 |
| EBITDA | -254.77M | 39.89M | -200.85M | -82.64M |
| EBIT | -255.68M | 38.80M | -201.34M | -82.69M |
| NetInterestIncome | 13.81M | 16.16M | 4.29M | 36.00K |
| InterestExpense | 0.00 | |||
| InterestIncome | 13.81M | 16.16M | 4.29M | 36.00K |
| NormalizedIncome | -242.75M | 49.27M | -198.38M | -87.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -301.74M | 49.27M | -198.38M | -87.93M |
| TotalExpenses | 343.05M | 341.98M | 223.57M | 82.69M |
| TotalOperatingIncomeAsReported | -314.73M | 38.80M | -201.34M | -82.69M |
| DilutedAverageShares | 68.14M | 69.99M | 58.50M | 55.22M |
| BasicAverageShares | 68.14M | 67.23M | 58.50M | 55.22M |
| DilutedEPS | -4.43 | 0.70 | -3.39 | -1.59 |
| BasicEPS | -4.43 | 0.73 | -3.39 | -1.59 |
| DilutedNIAvailtoComStockholders | -301.74M | 49.27M | -198.38M | -87.93M |
| NetIncomeCommonStockholders | -301.74M | 49.27M | -198.38M | -87.93M |
| NetIncome | -301.74M | 49.27M | -198.38M | -87.93M |
| NetIncomeIncludingNoncontrollingInterests | -301.74M | 49.27M | -198.38M | -87.93M |
| NetIncomeContinuousOperations | -301.74M | 49.27M | -198.38M | -87.93M |
| TaxProvision | -393.00K | 5.03M | 774.00K | 0.00 |
| PretaxIncome | -302.14M | 54.30M | -197.60M | -87.93M |
| OtherIncomeExpense | -60.27M | -660.00K | -551.00K | -5.28M |
| OtherNonOperatingIncomeExpenses | -1.21M | -660.00K | -551.00K | -5.28M |
| SpecialIncomeCharges | -59.05M | 0.00 | ||
| OtherSpecialCharges | 36.20M | |||
| RestructuringAndMergernAcquisition | 22.85M | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 13.81M | 16.16M | 4.29M | 36.00K |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 13.81M | 16.16M | 4.29M | 36.00K |
| OperatingIncome | -255.68M | 38.80M | -201.34M | -82.69M |
| OperatingExpense | 218.41M | 316.54M | 220.58M | 82.69M |
| OtherOperatingExpenses | -285.00K | |||
| ResearchAndDevelopment | 104.08M | 128.19M | 93.45M | 44.04M |
| SellingGeneralAndAdministration | 114.33M | 188.36M | 127.13M | 38.93M |
| GeneralAndAdministrativeExpense | 38.93M | |||
| OtherGandA | 38.93M | |||
| GrossProfit | -37.26M | 355.35M | 19.24M | 0.00 |
| CostOfRevenue | 124.63M | 25.44M | 2.99M | 0.00 |
| TotalRevenue | 87.37M | 380.79M | 22.23M | 0.00 |
| OperatingRevenue | 114.27M | 431.43M | 27.10M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 68.63M | 67.71M | 66.51M | 55.22M |
| ShareIssued | 68.63M | 67.71M | 66.51M | 55.22M |
| TotalDebt | 1.98M | 4.24M | 6.28M | 0.00 |
| TangibleBookValue | 164.76M | 433.43M | 340.61M | -151.17M |
| InvestedCapital | 164.76M | 433.43M | 340.61M | -151.17M |
| WorkingCapital | 161.03M | 382.62M | 335.52M | 87.56M |
| NetTangibleAssets | 164.76M | 433.43M | 340.61M | -151.17M |
| CapitalLeaseObligations | 1.98M | 4.24M | 6.28M | 0.00 |
| CommonStockEquity | 164.76M | 433.43M | 340.61M | -151.17M |
| TotalCapitalization | 164.76M | 433.43M | 340.61M | -151.17M |
| TotalEquityGrossMinorityInterest | 164.76M | 433.43M | 340.61M | -151.17M |
| StockholdersEquity | 164.76M | 433.43M | 340.61M | -151.17M |
| GainsLossesNotAffectingRetainedEarnings | -92.00K | 197.00K | -86.00K | 9.00K |
| OtherEquityAdjustments | -92.00K | 197.00K | -86.00K | 9.00K |
| RetainedEarnings | -606.69M | -304.95M | -354.22M | -155.84M |
| AdditionalPaidInCapital | 771.54M | 738.18M | 694.91M | 4.67M |
| CapitalStock | 7.00K | 7.00K | 7.00K | 1.00K |
| CommonStock | 7.00K | 7.00K | 7.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 28.87M | 84.02M | 50.85M | 256.78M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 463.00K | 1.98M | 4.24M | 239.39M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 239.35M | ||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | 35.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 463.00K | 1.98M | 4.24M | 0.00 |
| LongTermCapitalLeaseObligation | 463.00K | 1.98M | 4.24M | 0.00 |
| CurrentLiabilities | 28.41M | 82.04M | 46.61M | 17.40M |
| OtherCurrentLiabilities | 4.60M | |||
| CurrentDebtAndCapitalLeaseObligation | 1.52M | 2.26M | 2.04M | |
| CurrentCapitalLeaseObligation | 1.52M | 2.26M | 2.04M | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 9.99M | 16.79M | 15.23M | 4.28M |
| PayablesAndAccruedExpenses | 16.90M | 62.99M | 29.34M | 13.12M |
| CurrentAccruedExpenses | 13.96M | 40.93M | 23.08M | 8.74M |
| Payables | 2.94M | 22.06M | 6.26M | 4.37M |
| OtherPayable | 1.36M | |||
| AccountsPayable | 2.94M | 22.06M | 6.26M | 4.37M |
| TotalAssets | 193.63M | 517.45M | 391.45M | 105.61M |
| TotalNonCurrentAssets | 4.20M | 52.79M | 9.32M | 663.00K |
| OtherNonCurrentAssets | 1.47M | 46.38M | 1.19M | 189.00K |
| NetPPE | 2.73M | 6.41M | 8.13M | 474.00K |
| AccumulatedDepreciation | -1.36M | -1.63M | -540.00K | -53.00K |
| GrossPPE | 4.09M | 8.04M | 8.68M | 527.00K |
| Leases | 176.00K | 176.00K | 176.00K | 50.00K |
| ConstructionInProgress | 221.00K | 589.00K | 803.00K | 139.00K |
| OtherProperties | 1.77M | 3.73M | 5.52M | |
| MachineryFurnitureEquipment | 1.92M | 3.55M | 2.17M | 338.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 189.43M | 464.67M | 382.13M | 104.95M |
| OtherCurrentAssets | 12.48M | 14.93M | 10.11M | 5.39M |
| CurrentDeferredAssets | 0.00 | 3.44M | ||
| PrepaidAssets | 5.39M | |||
| Inventory | 0.00 | 38.32M | 9.77M | 0.00 |
| FinishedGoods | 0.00 | 937.00K | 0.00 | |
| WorkInProcess | 0.00 | 1.68M | 0.00 | |
| RawMaterials | 0.00 | 7.15M | 0.00 | |
| Receivables | 447.00K | 40.05M | 15.31M | 0.00 |
| AccountsReceivable | 447.00K | 40.05M | 15.31M | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 176.50M | 371.36M | 346.94M | 96.12M |
| OtherShortTermInvestments | 99.11M | 201.16M | 284.42M | 45.93M |
| CashAndCashEquivalents | 77.39M | 170.20M | 62.53M | 50.19M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -167.80M | 10.68M | -182.40M | -75.15M |
| RepaymentOfDebt | 0.00 | 0.00 | -263.00K | |
| IssuanceOfDebt | 0.00 | 0.00 | 26.16M | |
| IssuanceOfCapitalStock | 0.00 | 432.45M | 135.00M | |
| CapitalExpenditure | -157.00K | -1.24M | -2.53M | -353.00K |
| IncomeTaxPaidSupplementalData | 708.00K | 6.39M | 27.00K | 0.00 |
| EndCashPosition | 78.84M | 170.92M | 63.24M | 50.38M |
| BeginningCashPosition | 170.92M | 63.24M | 50.38M | 13.07M |
| EffectOfExchangeRateChanges | -438.00K | 160.00K | -65.00K | 13.00K |
| ChangesInCash | -91.64M | 107.52M | 12.93M | 37.30M |
| FinancingCashFlow | 348.00K | 3.54M | 431.79M | 158.51M |
| CashFlowFromContinuingFinancingActivities | 348.00K | 3.54M | 431.79M | 158.51M |
| NetOtherFinancingCharges | -1.78M | -3.45M | -2.85M | -2.73M |
| ProceedsFromStockOptionExercised | 2.13M | 6.99M | 2.19M | 343.00K |
| NetPreferredStockIssuance | 0.00 | 0.00 | 135.00M | |
| PreferredStockIssuance | 0.00 | 0.00 | 135.00M | |
| NetCommonStockIssuance | 0.00 | 432.45M | 0.00 | |
| CommonStockIssuance | 0.00 | 432.45M | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 25.90M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 25.90M | |
| LongTermDebtPayments | 0.00 | 0.00 | -263.00K | |
| LongTermDebtIssuance | 0.00 | 0.00 | 26.16M | |
| InvestingCashFlow | 75.65M | 92.05M | -238.99M | -46.41M |
| CashFlowFromContinuingInvestingActivities | 75.65M | 92.05M | -238.99M | -46.41M |
| NetOtherInvestingChanges | -36.20M | |||
| NetInvestmentPurchaseAndSale | 112.01M | 93.29M | -236.46M | -46.05M |
| SaleOfInvestment | 344.00M | 394.12M | 179.41M | 3.00M |
| PurchaseOfInvestment | -231.99M | -300.83M | -415.87M | -49.05M |
| NetPPEPurchaseAndSale | -157.00K | -1.24M | -2.53M | -353.00K |
| PurchaseOfPPE | -157.00K | -1.24M | -2.53M | -353.00K |
| OperatingCashFlow | -167.65M | 11.92M | -179.87M | -74.80M |
| CashFlowFromContinuingOperatingActivities | -167.65M | 11.92M | -179.87M | -74.80M |
| ChangeInWorkingCapital | -45.83M | -65.66M | -1.64M | 4.59M |
| ChangeInOtherCurrentLiabilities | -2.26M | -2.04M | -917.00K | 0.00 |
| ChangeInOtherCurrentAssets | 1.57M | 1.18M | 125.00K | |
| ChangeInPayablesAndAccruedExpense | -78.91M | 37.48M | 27.91M | 9.10M |
| ChangeInAccruedExpense | -59.81M | 21.60M | 26.05M | 8.43M |
| ChangeInInterestPayable | 0.00 | 0.00 | -2.00K | |
| ChangeInPayable | -19.10M | 15.88M | 1.85M | 670.00K |
| ChangeInAccountPayable | -19.10M | 15.88M | 1.85M | 670.00K |
| ChangeInPrepaidAssets | 4.99M | -3.23M | -5.22M | -4.49M |
| ChangeInInventory | -9.25M | -73.13M | -9.77M | 0.00 |
| ChangeInReceivables | 39.60M | -24.74M | -14.82M | -144.00K |
| ChangesInAccountReceivables | 39.60M | -24.74M | -15.31M | 0.00 |
| OtherNonCashItems | 37.16M | 5.23M | ||
| StockBasedCompensation | 33.04M | 37.16M | 21.71M | 3.14M |
| AssetImpairmentCharge | 118.68M | 0.00 | ||
| AmortizationOfSecurities | -9.86M | -9.94M | -2.06M | 121.00K |
| DepreciationAmortizationDepletion | 904.00K | 1.09M | 487.00K | 52.00K |
| DepreciationAndAmortization | 904.00K | 1.09M | 487.00K | 52.00K |
| Depreciation | 904.00K | 1.09M | 487.00K | 52.00K |
| NetIncomeFromContinuingOperations | -301.74M | 49.27M | -198.38M | -87.93M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AMLX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|